1
|
Clifford R, Lindman S, Zhu J, Luo E, Delmar J, Tao Y, Ren K, Lara A, Cayatte C, McTamney P, O'Connor E, Öhman J. Production of native recombinant proteins using a novel split intein affinity technology. J Chromatogr A 2024; 1724:464908. [PMID: 38669943 DOI: 10.1016/j.chroma.2024.464908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 04/09/2024] [Accepted: 04/11/2024] [Indexed: 04/28/2024]
Abstract
Affinity tags are frequently engineered into recombinant proteins to facilitate purification. Although this technique is powerful, removal of the tag is desired because the tag can interfere with biological activity and can potentially increase the immunogenicity of therapeutic proteins. Tag removal is complex, as it requires adding expensive protease enzymes. To overcome this limitation, split intein based affinity purification systems have been developed in which a CC-intein tag is engineered into a protein of interest for binding to a NC-intein peptide ligand fixed to a chromatographic support. Tag removal in these systems is achieved by creating an active intein-complex during protein capture, which triggers a precise self-cleavage reaction. In this work, we show applications of a new split intein system, Cytiva™ ProteinSelect™. One advantage of the new system is that the NC-intein ligand can be robustly produced and conjugated to large volumes of resin for production of gram scale proteins. SARS-CoV-2 spike protein receptor binding domain and a Bispecific T Cell Engager in this work were successfully captured on the affinity resin and scaled 10-fold. Another advantage of this system is the ability to sanitize the resin with sodium hydroxide without loosing the 10-20 g/L binding capacity. Binding studies with IL-1b and IFNAR-1 ECD showed that the resin can be regenerated and sanitized for up to 50 cycles without loosing binding capacity. Additionally, after several cycles of sanitization, binding capacity was retained for the SARS-CoV-2 spike protein receptor binding domain and a Bispecific T Cell Engager. As with other split intein systems, optimization was needed to achieve ideal expression and recovery. The N-terminal amino acid sequence of the protein of interest required engineering to enable the cleavage reaction. Additionally, ensuring the stability of the CC-intein tag was important to prevent premature cleavage or truncation. Controlling the hold time of the expression product and the prevention of protease activity prior to purification was needed. These results demonstrate the feasibility of the Cytiva™ ProteinSelect™ system to be used in academic and industrial research and development laboratories for the purification of novel proteins expressed in either bacterial or mammalian systems.
Collapse
Affiliation(s)
- Robert Clifford
- Purification Process Sciences, Process and Analytical Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | | | - Jie Zhu
- Cell Culture & Fermentation Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Ethan Luo
- Cell Culture & Fermentation Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Jared Delmar
- Physicochemical Development, Process and Analytical Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Yeqing Tao
- Physicochemical Development, Process and Analytical Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Kuishu Ren
- Virology and Targeted Therapeutics, Virology and Vaccine Discovery, Vaccines & Immune Therapies Unit, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Abigail Lara
- Immune Engagers, Early ICC Discovery, R&D Oncology, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Corinne Cayatte
- Immune Engagers, Early ICC Discovery, R&D Oncology, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Patrick McTamney
- Virology and Targeted Therapeutics, Virology and Vaccine Discovery, Vaccines & Immune Therapies Unit, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Ellen O'Connor
- Purification Process Sciences, Process and Analytical Sciences, R&D Biopharmaceuticals, AstraZeneca LLC, One Medimmune Way, Gaithersburg, MD 20878, USA.
| | - Johan Öhman
- Cytiva, Björkgatan 30, Uppsala, 753 23, Sweden
| |
Collapse
|
2
|
Zhou N, An T, Zhang Y, Zhao G, Wei C, Shen X, Li F, Wang X. Improving Photocleavage Efficiency of Photocleavable Protein for Antimicrobial Peptide Histatin 1 Expression. Protein Pept Lett 2024; 31:141-152. [PMID: 38243926 DOI: 10.2174/0109298665276722231212053009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 11/17/2023] [Accepted: 11/20/2023] [Indexed: 01/22/2024]
Abstract
BACKGROUND Antimicrobial peptides (AMPs) are promising alternative agents for antibiotics to overcome antibiotic resistance problems. But, it is difficult to produce large-scale antimicrobial research due to the toxicity towards expression hosts or degradation by peptidases in the host. Therefore, heterologous recombinant expression of antimicrobial peptides has always been a challenging issue. OBJECTIVES To overcome toxicity to the expression host and low expression level, a new photocleavable protein fusion expression method for antimicrobial peptides is provided.3 Methods: Through directed evolution and high throughput screening, a photocleavable protein mutant R6-2-6-4 with a higher photocleavage efficiency was obtained. The DNA coding sequence of antimicrobial peptide Histatin 1 was fused within the sequence of R6-2-6-4 gene. The fusion gene was successfully expressed in Escherichia coli expression system. RESULTS Antimicrobial peptide Histatin 1 could be successfully expressed and purified by fusing within PhoCl mutant R6-2-6-4. The antimicrobial activity was rarely affected, and the MIC value was 33 ug/mL, which was basically equivalent to 32 ug/mL of the chemically synthesized Histatin 1. After amplification in a 5 L fermenter, the expression of PhoCl mutant (R6-2-6-4)-Histatin1 improved up to 87.6 mg/L in fermenter, and Histatin1 obtained by photocleavage also could up to 11 mg/L. The prepared Histatin1 powder remained stable when stored at 4oC for up to 4 months without any degradation. In addition, the expression and photocleavage of β -Defensin105 and Lysostaphin verified the certain universality of the PhoCl mutant fusion expression system. CONCLUSION Antimicrobial peptides Histatin 1, β -Defensin 105 and Lysostaphin were successfully expressed and purified by photocleavable protein mutant. This may provide a novel strategy to express and purify antimicrobial peptides in the Escherichia coli expression system.
Collapse
Affiliation(s)
- Nana Zhou
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Tai An
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Yuan Zhang
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Guomiao Zhao
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Chao Wei
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Xuemei Shen
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Fan Li
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| | - Xiaoyan Wang
- Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
| |
Collapse
|
3
|
Lamer T, Vederas JC. Simplified cloning and isolation of peptides from "sandwiched" SUMO-peptide-intein fusion proteins. BMC Biotechnol 2023; 23:11. [PMID: 37020212 PMCID: PMC10074672 DOI: 10.1186/s12896-023-00779-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 03/28/2023] [Indexed: 04/07/2023] Open
Abstract
BACKGROUND Some peptides are targets for degradation when heterologously expressed as fusion proteins in E. coli, which can limit yields after isolation and purification. We recently reported that peptide degradation may be prevented by production of a "sandwiched" SUMO-peptide-intein (SPI) fusion protein, which protects the target peptide sequence from truncation and improves yield. This initial system required cloning with two commercially available vectors. It used an N-terminal polyhistidine tagged small ubiquitin-like modifier (SUMO) protein and a C-terminal engineered Mycobacterium xenopii DNA Gyrase A intein with an inserted chitin binding domain (CBD) to create "sandwiched" fusion proteins of the form: His6-SUMO-peptide-intein-CBD. However, the major drawback of this previously reported fusion protein "sandwich" approach is the increased time and number of steps required to complete the cloning and isolation procedures, relative to the simple procedures to produce recombinant peptides in E. coli from a single (non-"sandwiched") fusion protein system. RESULTS In this work we generate the plasmid pSPIH6, which improves upon the previous system by encoding both the SUMO and intein proteins and allows facile construction of a SPI protein in a single cloning step. Additionally, the Mxe GyrA intein encoded in pSPIH6 contains a C-terminal polyhistidine tag, resulting in SPI fusion proteins of the form: His6-SUMO-peptide-intein-CBD-His6. The dual polyhistidine tags greatly simplify isolation procedures compared to the original SPI system, which we have here demonstrated with two linear bacteriocin peptides: leucocin A and lactococcin A. The yields obtained for both peptides after purification were also improved compared to the previous SPI system as a result of this streamlined protocol. CONCLUSIONS This modified SPI system and its simplified cloning and purification procedures described here may be generally useful as a heterologous E. coli expression system to obtain pure peptides in high yield, especially when degradation of the target peptide is an issue.
Collapse
Affiliation(s)
- Tess Lamer
- Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Canada
| | - John C Vederas
- Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Canada.
| |
Collapse
|